Snake envenoming is recognized as a global health problem, affecting thousands of people every year. One of the main challenges in addressing this issue is the correct identification and treatment of these envenomations, mainly in locations where people don’t have easy access to hospitals. In Brazil, the genus Bothrops is responsible for the majority of envenomations, followed by Crotalus. This study reports a simple methodology for detecting raw venom from snakes of the genus Bothrops, through interaction with their corresponding antibodies, using a high-sensitivity optical biosensor. The protocol consists of adding antibodies (present in the commercial antivenom) to the sensor surface, followed by the addition of Crotalus venom (nonspecific), and then Bothrops venom (specific), resulting in changes in the refractive index, to evaluate cross reactions between them. Different concentrations of raw venom from snakes of the genus Bothrops and Crotalus were tested, starting with a concentration of 6.784μgmL−1 and progressing until reaching the minimum detectable concentration. The binding capacity of venom to antivenom was investigated at two concentrations of antivenom: 5 μgm−1 and 50 μgmL−1. Both antivenom and snake venoms were solubilized in phosphate buffered saline (PBS). The results show an accurate detection of the antigen of interest (Bothrops venom), tested at different concentrations. The biosensor was able to detect venom up to a concentration of 0.848 μgmL−1. In addition, no interference from nonspecific binding between the Bothrops antivenom and Crotalus venom was detected. The detection of specific venom (Bothrops) occurred in a satisfactory time (up to 14 minutes). The results provide evidence that the biosensor and the methodology employed can be considered a diagnostic model under development, which can help health workers to better identify and treat envenomated people.

The authors have declared no competing interest.

Yes

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

NONE

I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.

Yes

UPON REQUEST